“Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil”

Denis L. Jardim,1 Adriano Gonçalves e Silva,2 Alexandre Saad Fere Lima Pompeo,3,4 Alvaro Sadek Sarkis,5 Ana Paula Garcia Cardoso,6 Andre Deeke Sasse,7 Andre Poisl Fay,8 Andrey Soares,6,9,10 Antonio Carlos Lima Pompeo,11 Arie Carneiro,6 Ariel Galapo Kann,12 Camilla Fogassa,6 Celso Heitor De Freitas Junior,3 Daher Cezar Chade,13 Daniel Herchenhorn,10,14 Daniel Vargas Pivato De Almeida,15 Diogo Augusto Rodrigues Da Rosa,10,16 Evanius Garcia Wiermann,17 Fabio Augusto Barros Schutz,18 Fabio Roberto Kater,18 Fernando De Moura,18 Fernando Korkes,19,20 Fernando Meyer,21,22,23 Fernado Nunes Galvão De Oliveira,10,24 Fernando Sabino,10,25,26 Gilberto Laurino Almeida,27 Gúilherme Avanço,28 Gustavo Cardoso Guimaraes,18 Gustavo Caserta Lemos,20 Gustavo Franco Carvalhal,29,30 Hanna Kim,18 Igor Protzner Morbeck,1,31 Joao Carlos Campagnari,18,32 Jose Augusto Rinck Junior,33 José Ricardo Tuma Da Ponte,34 Karine Martins Da Trindade,10,35 Leonardo Atem,35 Leonardo Borges,20 Lucas Mendes Nogueira,36 Lucas Teixeira e Aquiar Batista,37,38

1Hospital Sírio Libanês, Sociedade Beneficente de Setentas, São Paulo, SP, Brasil
2Instituto de Câncer e Transplante, Curitiba, PR, Brasil
3Hospital Beneficência Portuguesa, Departamento de Uro-Oncologia, São Paulo, SP, Brasil
4Grupo de Uro-Oncologia do Hcct, São Paulo, SP, Brasil
5Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, SP, Brasil
6Hospital Israelita Albert Einstein, Departamento de Oncologia, São Paulo, SP, Brasil
7Grupo Sonhe, Campinas, SP, Brasil
8PUCRS School of Medicine, Porto Alegre, RS, Brasil
9Grupo Oncoclínicas, São Paulo, SP, Brasil
10Latin American Cooperative Oncology Group (LACOG), Genitourinary Group
11Sociedade Brasileira de Urologia, São Paulo, SP, Brasil
12Hospital Alencar Oswaldo, São Paulo, SP, Brasil
13Instituto do Câncer do Estado de São Paulo da Faculdade de Medicina da USP, São Paulo, SP, Brasil
14Rede D’Or, Rio de Janeiro, RJ, Brasil
15Grupo Oncoclínicas, Brasilia, DF, Brasil
16Grupo Oncoclínicas, Rio de Janeiro, RJ, Brasil
17Instituto de Oncologia do Paranhó, Curitiba, PR, Brasil
18Hospital Beneficência Portuguesa, Departamento de Oncologia, São Paulo, SP, Brasil
19Grupo de uro-oncologia da Faculdade de Medicina do ABC, Santo André, SP, Brasil
20Hospital Israelita Albert Einstein, Departamento de Urologia, São Paulo, SP, Brasil
21Sociedade Brasileira de Urologia, Curitiba, PR, Brasil
22Hospital Universitário Câncer de Porto Alegre (PUCPA), Curitiba, PR, Brasil
23Clínica de Oncologia do Grupo CAM (CLION), Salvador, BA, Brasil
24Hospital Santa Lucía, Brasília, DF, Brasil
25Hospital Universitário de Brasília, Brasília, DF, Brasil
26Universidade do Vale do Itajai (UNIVALI), Itajai, SC, Brasil
27Hospital Novo de Julho, São Paulo, SP, Brasil
28Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brasil

39Hospital Moinhos de Vento, Porto Alegre, RS, Brasil
40Universidade Católica de Brasília, Brasília, DF, Brasil
41Clínica de Urologia e Neonatologia, São Paulo, SP, Brasil
42A.C. Camargo Cancer Center, São Paulo, SP, Brasil
43Hospital Ophir Loyola, Belém, PA, Brasil
44Rede D’Or, Fortaleza, CE, Brasil
45Hospital dasClínicas da Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brasil
46Universidade Federal da Bahia, Salvador, BA, Brasil
47Hospital Cardio Pulmonar, Salvador, BA, Brasil
48Hospital Porto Dias, Department of Medical Oncology, Belém, Pará, Brasil
49Universidade Federal de São Paulo (UNIFESP), São Paulo, SP, Brasil
50Hospital Erasto Gaertner, Curitiba, PR, Brasil
51Faculdade de Medicina de Ribeirão Preto – USP (FMRP), Ribeirão Preto, SP, Brasil
52Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, SP, Brasil
53Inmanheid da Santa Casa de Misericórdia de São Paulo – Hospital Central, São Paulo, SP, Brasil
54Centro de Tratamento Oncológico (CTO), Belém, PA, Brasil
55Hospital Adventista de Belém (HAB), Belém, PA, Brasil
56Instituto D’Or de Ensino e Pesquisa, Salvador, BA, Brasil
57Rede D’Or, Salvador, BA, Brasil

Submitted: May 9, 2022; Revised: Aug 30, 2022; Accepted: Sep 6, 2022; Epub: xxx

Address for correspondence: Fernando C. Maluf, MD, PhD, Clinical Oncology Department, “Beneficência Portuguesa de São Paulo” Hospital, Rua Marmiriano de Carvalho 951, 01321-001, São Paulo, SP, Brasil.

E-mail contact: malufc@uol.com.br
Manuel Caitano Maia,1,39 Marcus Vinicius Sadi,40 Maria Alzira Almeida Rocha,6 Murilo De Almeida Luz,18,41 Oren Smalez,6 Paulo Sergio Moraes Lages,15 Raquel Midori Koga Matuda,15 Rodolfo Borges Dos Reis,42 Rodrigo Frota Indio,14 Roni De Carvalho Fernandes,43,44 Sandro Roberto Cavallero,45,46 Vinicius Carrera Souza,47,48 Wilson Busato Jr,27 Wladimir Alfer Junior,20 Fernando Maluf18,20

Abstract

A panel of Brazilian experts convened in order to provide recommendations regarding staging methods, antineoplastic therapy, osteoclast-targeted therapy, and patient follow-up in non-metastatic, castration-resistant prostate cancer. Key points include the reliance on prostate-specific antigen doubling time for treatment decisions, the absence of a clear preference between conventional and novel imaging techniques, and the increasing role of novel androgen-receptor signaling inhibitors.

Introduction: Non-metastatic, castration-resistant prostate cancer (nmCRPC) is an important clinical stage of prostate cancer, prior to morbidity and mortality from clinical metastases. In particular, the introduction of novel androgen-receptor signaling inhibitors (ARSi) has changed the therapeutic landscape in nmCRPC. Given recent developments in this field, we update our recommendations for the management of nmCRPC. Methods: A panel of 51 invited medical oncologists and urologists convened in May of 2021 with the aim of discussing and providing recommendations regarding the most relevant issues concerning staging methods, antineoplastic therapy, osteoclast-targeted therapy, and patient follow-up in nmCRPC. Panel members considered the available evidence and their practical experience to address the 73 multiple-choice questions presented. Results: Key recommendations and findings include the reliance on prostate-specific antigen doubling time for treatment decisions, the absence of a clear preference between conventional and novel (i.e., positron-emission tomography-based) imaging techniques, the increasing role of ARSi in various settings, the general view that ARSi have similar efficacy. Panelists highlighted the slight preference for darolutamide, when safety is of greater concern, and a continued need to develop high-level evidence to guide the intensity of follow-up in this subset of prostate cancer. Discussion: Despite the limitations associated with a consensus panel, the topics addressed are relevant in current practice, and the recommendations can help practicing clinicians to provide state-of-the-art treatment to patients with nmCRPC in Brazil and other countries with similar healthcare settings.

Clinical Genitourinary Cancer, Vol. 000, No.xxx, 1–12 © 2022 Published by Elsevier Inc.

Keywords: Prostate cancer, Non-metastatic, Castration-resistant prostate cancer, Practice guidelines, Androgen-receptor signalling inhibitors

Introduction

Prostate cancer is currently responsible for one out of seven new cancer cases in males worldwide.1 For clinical practice, prostate cancer can be divided into clinical states, with specific diagnostic evaluation and therapeutic options. Progression during androgen-deprivation therapy (ADT) is a key milestone in that attempt, marking the onset of the castration-resistant state in a given patient.2,3 When biochemical progression is detected in patients on ADT, generally after radical prostatectomy and/or radiotherapy to the prostate, and distant disease cannot be identified by imaging, non-metastatic, castration-resistant prostate cancer (nmCRPC) is defined.3,4 More specifically, a 25% increase in prostate-specific antigen (PSA) levels from nadir (considering a starting value ≥1.0 ng/mL, and a minimum rise of 2.0 ng/mL) is required in the presence of castrate testosterone levels (<50 ng/dL) and absence of disease identified by computed tomography (CT) or magnetic resonance imaging (MRI), in lymph nodes beyond the true pelvis or in visceral organs, and by bone scan.5

The prevalence of nmCRPC is estimated to be between 2% and 8% in different countries.5 In recent years, there has been an increased ability to identify these patients, partly as a result of more frequent PSA testing for men on treatment with ADT.6 Moreover, there is growing interest in identifying patients with nmCRPC, for a variety of reasons. First, results from placebo arms in clinical trials among patients with nmCRPC suggest that up to 60% of these patients develop overt metastatic disease within 3 to 5 years.6,7,8 The presence of clinical metastases is associated with morbidity from the disease and metastatic CRPC (mCRPC) is considered a lethal state of prostate cancer.9 Based on the previously mentioned model, nmCRPC represents a patient population for whom preventing or delaying a transition to mCRPC is the primary therapeutic objective, with potential impact even in the public-health perspective.9,10 Secondly, the introduction of the novel androgen-receptor signalling inhibitors (ARSi, apalutamide, darolutamide and enzalutamide) has changed the therapeutic landscape in the various stages along the continuum of prostate cancer progression and offered improved options in nmCRPC.2,10 Finally, novel imaging methods are more
accurate in detecting lymph-node and distant metastases in patients with biochemical recurrence, thus bringing a new perspective to disease staging in patients with CRPC.\textsuperscript{2,5,11,12}

Our group has previously reviewed and provided recommendations for staging, diagnosis and treatment of nmCRPC in Brazil through a consensus conference.\textsuperscript{13} Given recent developments in imaging and treatment modalities, we sought to update our recommendations for practicing physicians in Brazil, especially due to the epidemiological importance of prostate cancer in this country.\textsuperscript{14}

Patients and Methods
Panel organization, composition, and goals
The expert panel was composed by 51 invited medical oncologists and urologists with expertise in genitourinary malignancies in Brazil. The number of experts in the panel was increased compared to prior consensus to better assess the regional differences in Brazil. In addition, specialists were selected based on local clinical practices, and usually urologists and oncologists assist patients with nmCRPC. Radiotherapy was discussed as part of the questions, but there were no radiotherapists as panel members, as no recommendations of radiotherapy were derived from first consensus edition. The meeting was organized and coordinated by the two senior authors (DJJ and FM) and aimed at discussing the most relevant issues concerning the diagnosis and treatment of patients with nmCRPC, including staging methods, antineoplastic therapy, osteoclast-targeted therapy, and patient follow-up. A total of 73 multiple-choice questions were developed on these topics. In a modified Delphi process, a scientific committee reviewed questions in three rounds for inputs and recommendations. Questions were presented to the expert panel, which convened in May of 2021 (see Supplementary Materials for the complete text of these questions, which appear in Results in an abbreviated format). In order to provide their recommendations, panel members considered the published scientific evidence and their practical experience on the issues discussed. For all the questions, it was assumed that the interventions discussed were approved and available, whereas those not yet approved in Brazil were not presented among the possible options.

Statistical analysis

Results were computed descriptively for each of the multiple-choice questions addressed by the panel. When answering each question, the option “abstain” was to be used when a panel member felt impeded to provide a qualified response for a lack of knowledge or the presence of conflicts of interest. The consensus was considered to be present for a question if at least 75% of the voting members selected a particular answer, considering the number of voters and the option “abstain” in the denominator of this proportion. When an answer garnered between 50.0% and 74.9% of votes, this was considered as a majority recommendation.

Results
Staging methods

As shown in Table 1, there was no consensus for any of the three questions on staging methods. Regarding imaging modalities for patients with nmCRPC, voters were equally divided between (1) positron-emission tomography (PET)-CT with prostate-specific membrane antigen (PSMA) (or PET-MRI with PSMA), with or without pelvic MRI and (2) chest CT or X-ray, CT of the abdomen and pelvis (or pelvic MRI) and bone scan, both in case of recurrences after radical prostatectomy and after curatively intended radiotherapy. Regarding the preferred method for calculating PSA doubling time (PSAdt), two-thirds of voters recommended using an electronic calculator and the last three PSA values above 0.1 ng/mL. Table 1 also shows a question addressing treatment options, which is presented here because the recommendation with the largest percentage of votes (45.2%) was for PSMA-based PET scanning in a hypothetical patient with small pelvic lymph nodes.

Antineoplastic therapy

There were 65 questions addressing systemic antineoplastic therapy for patients with nmCRPC, one of which presented in Table 1. The first eight of the remaining 64 questions elicited recommendations for a newly diagnosed patient with different combinations of PSA level, PSAdt, and life expectancy. The panel recommendations for these eight hypothetical patients are summarized in Figure 1. There was consensus for five of these questions, majority vote for one, and relatively similar division of votes between two different recommendations for two questions.

Table 2 presents recommendations regarding the specific choice of agents, particularly novel ARSi. There was consensus for only one of eight questions, namely about the adequacy of any novel ARSi when taking overall survival results into account. There was also a general trend for recommending any of these agents instead of anyone in particular, except for a preference for darolutamide when safety or tolerability was taken into account. Toxicity and access were the main reasons for recommendations regarding the choice of novel ARSi. Of note, there was a considerable lack of consensus about whether positive PSMA-based imaging should change management when conventional imaging has disclosed no metastatic disease, and on how to treat these patients.

The next series of questions addressed drug choice in view of concern with specific comorbidities or age groups among patients with a reasonable life expectancy. As shown in Table 3, voters generally indicated any ARSi as the first option for most groups of patients with specific comorbidities. Exceptions to this were the preference for darolutamide specifically for patients with mental impairment or a history of falls or of seizures, as well as the use of drugs that increase the risk of seizures. Of note, the panel emphasized the importance of checking for drug interactions before treatment decisions for patients on multiple medications.

The following 30 questions aimed to elicit the level of concern among panel members regarding specific types of toxicity from each of the three novel ARSi. The results are displayed graphically in Figure 2. For most combinations of toxicity types and agents, the level of concern indicated by the panel was low (green in Figure 2) or moderate (yellow). However, as a general rule, there was higher concern with enzalutamide, intermediate with apalutamide, and lower with darolutamide.

The final seven questions related to treatment addressed various decisions that are often required upon observation of clinical events (Table 4). There was consensus for only two of those questions: (1) docetaxel is the treatment of choice (90.7%) for patients develop-
Osteoclast-targeted therapy

Four questions were posed to the panel to elicit recommendations on the use of osteoclast-targeted therapy to prevent skeletal-related events (SREs) in patients with nmCRPC (Table 5). Even though the percentage of panel members stating they do not recommend osteoclast-targeted therapy in this setting is below 75% for the first question, the other three questions make it clear that there was consensus that these agents are not indicated to prevent SREs in patients with nmCRPC.

Patient follow-up

Regarding the overall strategy for follow-up patients with nmCRPC on active therapy, 50.0% of panelists recommended physical examination and PSA levels every 3-6 months and a bone scan every 3-6 months, whereas 37.5% recommended physical examination and PSA levels every 3-6 months and imaging only in the case of symptoms. Physical examination and PSA levels every 3-6 months and a bone scan every 3-6 months, plus a chest CT or X-ray and CT of the abdomen every 3-6 months was recommended by 5% of members. No panel members recommended PET-PSMA and whole-body MRI, and 2.5% of voters recommended either (1) physical examination and PSA levels every 3-6 months with abdominal ultrasound and chest X-ray every 3-6 months and bone scan annually or (2) physical examination and PSA levels every 3-6 months and a chest CT or X-ray and CT of the abdomen and pelvis every 3-6 months. Finally, the abstention rate was 2.5%.

Discussion

Staging methods

Likely because of its established role in risk stratification, the PSA
t levels is used by the vast majority of panel voters, notwithstanding differences in the number of PSA values used (Table 1). As in the previous edition of this expert panel, the predominant recom-

Table 1 Questions related to staging methods.

<table>
<thead>
<tr>
<th>Question</th>
<th>Recommendations and percentages</th>
<th>Imaging for a nmCRPC patient after radical prostatectomy</th>
<th>Imaging for a nmCRPC patient after curatively intended radiotherapy</th>
<th>Calculation of PSA doubling time (based on values (&gt;0.1 ng/mL))</th>
<th>Approach to nmCRPC with pelvic lymph nodes ~2.0 cm in minor axis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Imaging for a nmCRPC patient after radical prostatectomy</td>
<td>PSMA PET-CT (or PSMA PET-MRI) +/- pelvic MRI</td>
<td>Whole-body MRI</td>
<td>Bone scan</td>
<td>Pelvic MRI</td>
<td>Pelvic MRI and bone scan</td>
</tr>
<tr>
<td>Imaging for a nmCRPC patient after curatively intended radiotherapy</td>
<td>PSMA PET-CT (or PSMA PET-MRI) +/- pelvic MRI</td>
<td>Whole-body MRI</td>
<td>Bone scan</td>
<td>Pelvic MRI</td>
<td>Pelvic MRI and bone scan</td>
</tr>
<tr>
<td>Calculation of PSA doubling time (based on values (&gt;0.1 ng/mL))</td>
<td>Do not calculate it</td>
<td>Last 2 values, manually</td>
<td>Last 2 values, electronically</td>
<td>Last 3 values, manually</td>
<td>Last 3 values, electronically</td>
</tr>
<tr>
<td>Approach to nmCRPC with pelvic lymph nodes ~2.0 cm in minor axis</td>
<td>Apa</td>
<td>Enza</td>
<td>Daro</td>
<td>Apa or enza or daro</td>
<td>Bic or flutax or nilu</td>
</tr>
<tr>
<td>PSA levels</td>
<td>2.4%</td>
<td>0</td>
<td>0</td>
<td>40.5%</td>
<td>0</td>
</tr>
</tbody>
</table>

Answers to some questions may not total 100% due to rounding.

A & P, abdomen and pelvis; Apa, apalutamide; Bica, bicalutamide; CT, computed tomography; Daro, darolutamide; Enza, enzalutamide; Fluta, flutax; Fluta, flutax; MRI, magnetic resonance imaging; Nilo, nilutamide; nmCRPC, non-metastatic, castration-resistant prostate cancer; PET, positron-emission tomography; PSMA, prostate-specific membrane antigen.

Please cite this article as: Denis L. Jardim et al, "Non-metastatic, Castration-resistant Prostate Cancer: Diagnostic and Treatment Recommendations by an Expert Panel from Brazil", Clinical Genitourinary Cancer, https://doi.org/10.1016/j.cjc.2022.09.005
Figure 1  Questions related to immediate management of patients with non-metastatic, castration-resistant prostate cancer. Answers to some questions may not total 100% due to rounding. Abbreviations: nmCRPC, non-metastatic, castration-resistant prostate cancer; PSA, prostate-specific antigen; PSADT, prostate-specific antigen doubling time.

Figure 1: Decision tree for immediate management of patients with non-metastatic, castration-resistant prostate cancer. 

Most nmCRPC patients

Life expectancy >10-15 years

PSADT ≤10 months

PSA ≥2 ng/mL
87.2% Apalutamide or enzalutamide or darolutamide
7.7% Darolutamide
5.1% No systemic therapy before clinical metastases
0 Apalutamide / Enzalutamide / Darolutamide or flutamide or nilutamide / Abstain

PSA <2 ng/mL
50.0% Apalutamide or enzalutamide or darolutamide
44.7% No systemic therapy before PSA ≥2 ng/mL
2.6% Darolutamide
2.6% No systemic therapy before clinical metastases
0 Apalutamide / Enzalutamide / Darolutamide or flutamide or nilutamide / Abstain

PSADT >10 months

PSA ≥2 ng/mL
68.3% No systemic therapy before PSADT ≤10 months
17.1% Apalutamide or enzalutamide or darolutamide
9.8% No systemic therapy before clinical metastases
2.4% Abstain
2.4% Abstain

PSA <2 ng/mL
75.0% No systemic therapy before PSADT ≤10 months
20.0% No systemic therapy before clinical metastases
2.5% Apalutamide or enzalutamide or darolutamide
2.5% Abstain
0 Apalutamide / Enzalutamide / Darolutamide or flutamide or nilutamide

Life expectancy <10-15 years

PSADT ≤10 months

PSA ≥2 ng/mL
78.6% Apalutamide or enzalutamide or darolutamide
16.7% No systemic therapy before clinical metastases
4.8% Darolutamide
0 Apalutamide / Enzalutamide / Darolutamide or flutamide or nilutamide / Abstain

PSA <2 ng/mL
44.2% Apalutamide or enzalutamide or darolutamide
44.2% No systemic therapy before PSA ≥2 ng/mL
7.0% No systemic therapy before clinical metastases
2.3% Darolutamide
0 Apalutamide / Enzalutamide / Darolutamide or flutamide or nilutamide / Abstain

PSADT >10 months

PSA ≥2 ng/mL
81.4% No systemic therapy before PSADT ≤10 months
11.6% No systemic therapy before clinical metastases
4.7% Apalutamide or enzalutamide or darolutamide
2.3% Darolutamide
0 Apalutamide / Enzalutamide / Darolutamide or flutamide or nilutamide / Abstain

PSA <2 ng/mL
86.0% No systemic therapy before PSADT ≤10 months
14.0% No systemic therapy before clinical metastases
0 Apalutamide or enzalutamide or darolutamide / Apalutamide / Enzalutamide / Darolutamide / Flutamide or nilutamide / Abstain

Recommendation (66.7%) is to compute the PSAdt using the last three PSA levels and an electronic system. Interestingly, the lack of consensus—and dichotomy of recommendations between conventional and novel techniques—for the questions on imaging methods also recapitulates the results of the first version of this expert panel (Table 1). These recommendations are consistent with individual clinical practice and likely related to the technology available in different institutions. PET-CT (or PET-MRI) imaging with PSMA is not available in public centers and is only available in some private centers in Brazil, a country with a dual healthcare system whereby services are provided under government funding or through private insurance. However, it is conceivable that different opinions about the role of novel imaging methods stem from different philosophical perceptions about the role of systemic therapy in different stages of the continuum of prostate cancer, particularly the transition between the non-metastatic and the oligometastatic state. Since this possibility has not been addressed by the panel, it remains speculative.
Of note, the National Comprehensive Cancer Network (NCCN) guidelines support the use of conventional imaging in this setting. Moreover, the definition of nmCRPC is not yet based on the need to rule out metastatic disease by more sensitive imaging modalities and is still largely based on conventional imaging. In randomized trials of systemic therapy for patients with nmCRPC, eligibility was based on absence of metastases by conventional imaging. However, this is an evolving field, and a recent randomized trial indicated that PET-CT with PSMA is superior to conventional imaging for detection of systemic disease in the setting of high-risk disease before curative-intent surgery or radiotherapy. Likewise, a meta-analysis assessing the role of Gallium-PSMA scanning showed that, among patients with biochemical recurrence, the percentage of positive scans rises proportionally according to PSA levels. Finally, a recent large retrospective study showed that PSMA-PET is able to detect M1 disease in 55% of patients previously diagnosed with nmCRPC. Therefore, further studies are needed to clarify the role of PSMA-based imaging in defining nmCRPC. Of note, as of today, no prospective trial demonstrated a clinical benefit in adding next-generation imaging for staging nmCRPC. Further-

<table>
<thead>
<tr>
<th>Question</th>
<th>Recommendations and percentages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antiandrogen preference in nmCRPC</td>
<td>Apa</td>
</tr>
<tr>
<td>4.4%</td>
<td>2.2%</td>
</tr>
<tr>
<td>Change of management if positive PSMA-based and negative conventional imaging</td>
<td>Yes</td>
</tr>
<tr>
<td>Treatment if positive PSMA-based and negative conventional imaging</td>
<td>Apa</td>
</tr>
<tr>
<td>52.3%</td>
<td>47.7%</td>
</tr>
<tr>
<td>Drug preference given survival data</td>
<td>Apa</td>
</tr>
<tr>
<td>0</td>
<td>8.8%</td>
</tr>
<tr>
<td>Drug preference given QOL data</td>
<td>Apa</td>
</tr>
<tr>
<td>2.4%</td>
<td>0</td>
</tr>
<tr>
<td>Drug preference given safety</td>
<td>Apa</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Drug preference given tolerability</td>
<td>Apa</td>
</tr>
<tr>
<td>2.4%</td>
<td>0</td>
</tr>
<tr>
<td>Reason for drug preference</td>
<td>Toxicity profile</td>
</tr>
<tr>
<td>50.0%</td>
<td>4.8%</td>
</tr>
<tr>
<td>When to stop treatment and start a new one in nmCRPC</td>
<td>PSA progression alone</td>
</tr>
<tr>
<td>2.3%</td>
<td>0</td>
</tr>
</tbody>
</table>

Answers to some questions may not total 100% due to rounding.

Apa, apalutamide; Bica, bicalutamide; Daro, darolutamide; Enza, enzalutamide; Fluta, flutamide; Nilo, nilutamide; nmCRPC, non-metastatic, castration-resistant prostate cancer; PSMA, prostate-specific membrane antigen; QOL, quality of life.
more, there is no evidence that metastasis-directed therapy beside newer systemic treatments with novel ARSi will modify the natural course of nmCRPC.

Finally, the recommendation by nearly half of the panel members to consider PSMA-based imaging in patients with small pelvic lymph nodes was balanced by a similar percentage of recommendations for immediate treatment. It should be noted that the Selective Prostate Androgen Receptor Targeting with ARN-509 (SPARTAN) trial of apalutamide, the Androgen Receptor Antagonizing Agent for Metastasis-free Survival (ARAMIS) trial of darolutamide, and the PROSPER trial of enzalutamide allowed the inclusion of patients presenting pelvic lymph nodes below the aortic bifurcation (measuring <2 cm for SPARTAN and ARAMIS, and <1.5 cm for PROSPER).16-18,23-25

**Antiandrogen therapy for nmCRPC**

Considering a newly diagnosed patient with nmCRPC, there was consensus among panel members (87.2%) that any of the novel ARSi would be the treatment of choice for initial management of most men with a life expectancy >10-15 years, a PSA≤d <10 months and a serum PSA ≥2 ng/mL. These characteristics are consistent with the criteria that led to eligibility to the three pivotal

---

Table 3: Questions related to comorbidities.

<table>
<thead>
<tr>
<th>Question</th>
<th>Drug choice for most patients with reasonable life expectancy and...</th>
<th>Recommendations and percentages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderate/severe diabetes</td>
<td>Apa or enza or daro</td>
<td>Apa</td>
</tr>
<tr>
<td></td>
<td>81.0%</td>
<td>0</td>
</tr>
<tr>
<td>Moderate/severe hypertension</td>
<td>Apa or enza or daro</td>
<td>Apa</td>
</tr>
<tr>
<td></td>
<td>54.8%</td>
<td>7.1%</td>
</tr>
<tr>
<td>Congestive heart failure &gt; Class II</td>
<td>Apa or enza or daro</td>
<td>Apa</td>
</tr>
<tr>
<td></td>
<td>59.1%</td>
<td>4.5%</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td>Apa or enza or daro</td>
<td>Apa</td>
</tr>
<tr>
<td></td>
<td>71.4%</td>
<td>4.8%</td>
</tr>
<tr>
<td>History of seizure or drugs that increase risk of seizure</td>
<td>Apa or enza or daro</td>
<td>Apa</td>
</tr>
<tr>
<td></td>
<td>11.1%</td>
<td>8.9%</td>
</tr>
<tr>
<td>Mental impairment</td>
<td>Apa or enza or daro</td>
<td>Apa</td>
</tr>
<tr>
<td></td>
<td>15.6%</td>
<td>2.2%</td>
</tr>
<tr>
<td>Renal insufficiency</td>
<td>Apa or enza or daro</td>
<td>Apa</td>
</tr>
<tr>
<td></td>
<td>78.6%</td>
<td>0</td>
</tr>
<tr>
<td>Age &gt;75 years</td>
<td>Apa or enza or daro</td>
<td>Apa</td>
</tr>
<tr>
<td></td>
<td>78.6%</td>
<td>0</td>
</tr>
<tr>
<td>History of falls</td>
<td>Apa or enza or daro</td>
<td>Apa</td>
</tr>
<tr>
<td></td>
<td>34.9%</td>
<td>2.3%</td>
</tr>
<tr>
<td>Osteopenia/osteoporosis</td>
<td>Apa or enza or daro</td>
<td>Apa</td>
</tr>
<tr>
<td></td>
<td>75.0%</td>
<td>0</td>
</tr>
<tr>
<td>On multiple medications</td>
<td>Apa or enza or daro</td>
<td>Apa</td>
</tr>
<tr>
<td></td>
<td>17.4%</td>
<td>0</td>
</tr>
</tbody>
</table>

Answers to some questions may not total 100% due to rounding.

Apa, apalutamide; Bica, bicalutamide; Daro, darolutamide; Enza, enzalutamide; Fluta, flutamide; Nilu, nilutamide; nmCRPC, non-metastatic, castration-resistant prostate cancer.
trials of these agents. Likewise, there was also consensus for no systemic therapy in three other combinations of these patient characteristics which were not consistent with the eligibility criteria to the pivotal trials, as well as majority vote (68.3%) for no systemic therapy for a fourth combination. However, the specific setting of life expectancy <10-15 years PSA \( \leq \) 10 months and a serum PSA \( \geq \) 2 ng/mL also led to consensus recommendation (78.6%) of any of the novel androgen-signal inhibitors, even though life expectancy was not defined in this way as an entry criterion for the pivotal trials. Finally, for two combinations of PSA \( \leq \) 10 months and a serum PSA <2 ng/mL, panel members were similarly divided between recommending any of the novel androgen-signal inhibitors or no systemic therapy until further PSA rises, something that reflects the current uncertainty in this field.

The panel reached consensus or majority vote for some of the various decisions that are often required during treatment of patients with nmCRPC. Chemotherapy plays a key role in the management of patients progressing to mCRPC, and consensus or majority recommendations were achieved for the use of docetaxel for patients who progressed to mCRPC (regardless of time to castration resistance of PFS while on ARSi). These results are supported in the literature by the description of cross-resistance between ARSi and findings of limited responses when sequencing treatment with two ARSi. When asked about the decision to change treatment in patients with nmCRPC, nearly half of panel members indicated that two methods (PSA, clinical and radiological assessment) to ascertain progression should be used to trigger such a change, whereas nearly a third recommended clinical and radiological progression as the triggers. In ARAMIS, PROSPER and SPARTAN, the experimental agent (respectively darolutamide, enzalutamide and apalutamide) was discontinued when there was clinical or radiological progression, or given prespecified levels of toxicity.

**Choice of specific novel androgen-signal inhibitors**

The lack of consensus about whether a positive PSMA-based imaging should change management when conventional imaging has disclosed no metastatic disease reflects the corresponding doubts in the current literature. Regarding the specific choice of novel ARSi, only apalutamide and enzalutamide were approved by the Brazilian regulatory authority (Anvisa) when the first edition of this expert panel was conducted. Likewise, another previous consensus-development panel from Brazil was conducted before...
Table 4  Questions related to decisions during treatment.

<table>
<thead>
<tr>
<th>Question</th>
<th>PSA progression alone</th>
<th>Clinical progression alone</th>
<th>Radiological progression alone</th>
<th>At least two criteria</th>
<th>Clinical and radiological progression</th>
<th>Any progression</th>
<th>Abstain</th>
<th>–</th>
</tr>
</thead>
<tbody>
<tr>
<td>When to stop treatment and start a new one in nmCRPC</td>
<td>2.3%</td>
<td>0</td>
<td>9.3%</td>
<td>51.2%</td>
<td>27.9%</td>
<td>9.3%</td>
<td>0</td>
<td>–</td>
</tr>
<tr>
<td>Choice for a patient requiring interruption of ASI for toxicity</td>
<td>Discontinue ASI and maintain castration</td>
<td>Wait for resolution and re-initiate same ASI</td>
<td>Switch to a different antiandrogen</td>
<td>Abstain</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Next choice for a patient on ASI for nmCRPC with short PFS</td>
<td>Enza if not used before</td>
<td>Abiraterone</td>
<td>Docetaxel</td>
<td>Radium-223 if only bone metastases</td>
<td>Cabazitaxel</td>
<td>Bic or flu or nilu</td>
<td>PARPi if DDR positive</td>
<td>Abstain</td>
</tr>
<tr>
<td>Next choice for a patient on ASI for nmCRPC with long PFS</td>
<td>Enza if not used before</td>
<td>Abiraterone</td>
<td>Docetaxel</td>
<td>Radium-223 if only bone metastases</td>
<td>Cabazitaxel</td>
<td>Bic or flu or nilu</td>
<td>PARPi if DDR positive</td>
<td>Abstain</td>
</tr>
<tr>
<td>Choice for a patient with clinical metastases after failing treatment for nmCRPC who previously progressed to CRPC in less than 12 months</td>
<td>Enza if not used before</td>
<td>Abiraterone</td>
<td>Docetaxel</td>
<td>Radium-223 if only bone metastases</td>
<td>Cabazitaxel</td>
<td>Bic or flu or nilu</td>
<td>PARPi if DDR positive</td>
<td>Abstain</td>
</tr>
<tr>
<td>Choice for a patient with clinical metastases after failing treatment for nmCRPC who previously progressed to CRPC in more than 12 months</td>
<td>Enza if not used before</td>
<td>Abiraterone</td>
<td>Docetaxel</td>
<td>Radium-223 if only bone metastases</td>
<td>Cabazitaxel</td>
<td>Bic or flu or nilu</td>
<td>PARPi if DDR positive</td>
<td>Abstain</td>
</tr>
<tr>
<td>Choice for a nmCRPC patient on ASI and PSA response to &lt;0.2 ng/mL</td>
<td>Continue therapy</td>
<td>Discontinue antiandrogen after 1 year</td>
<td>Discontinue antiandrogen after 2 years</td>
<td>Consider intermittent therapy</td>
<td>Abstain</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

Answers to some questions may not total 100% due to rounding.
ASI, androgen-signal inhibitor; Bica, bicalutamide; DDR, DNA-damage repair; Enza, enzalutamide; Fluta, flutamide; MFS, metastasis-free survival; Nilv, nilutamide; nmCRPC, non-metastatic, castration-resistant prostate cancer; PARPi, poly (ADP-ribose) polymerase inhibitor.

the approval of darolutamide in this country.29 Given the recent approval of darolutamide by Anvisa, there was considerable interest in assessing the comparative perception of these three agents. Interestingly, the panel indicated a seeming lack of clear preference for any specific agent when taking overall survival or quality of life into account, given positive results from all three agents.23-25,30-32 Nevertheless, when one specific agent was indicated in light of considerations about safety, tolerability and quality of life, darolutamide was the drug garnering more votes, likely as a consequence of more impactful results in these domains in comparison with placebo in the ARAMIS trial31 and in indirect comparison with apalutamide and enzalutamide.33-36

Even though novel ARSi are generally safe, toxicity is a major consideration when choosing treatment for this patient population, asymptomatic from the viewpoint of prostate cancer and typically with a long life expectancy. Apalutamide, darolutamide and enzalutamide are associated with variable rates of decreased appetite, fatigue, nausea, hot flashes, fractures, falls, skin rash, hyper-
### Table 5: Questions related to osteoclast-targeted therapy.

<table>
<thead>
<tr>
<th>Question</th>
<th>Zoledronic acid</th>
<th>Denosumab</th>
<th>Either</th>
<th>Another osteoclast-targeted therapy</th>
<th>Recommendations and percentages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Choice of osteoclast-targeted therapy to prevent SREs in nmCRPC</td>
<td>4.3%</td>
<td>6.5%</td>
<td>15.2%</td>
<td>0</td>
<td>I do not use this therapy in this setting, but may supplement calcium and vitamin D</td>
</tr>
<tr>
<td>Treatment frequency for zoledronic acid as prevention of SREs in nmCRPC</td>
<td>Every 12 months</td>
<td>Every 6 months</td>
<td>Every 3 months</td>
<td>Every month</td>
<td>I do not use this therapy in this setting</td>
</tr>
<tr>
<td>Treatment frequency for denosumab as prevention of SREs in nmCRPC</td>
<td>Every 12 months</td>
<td>Every 6 months</td>
<td>Every 3 months</td>
<td>Every month</td>
<td>I do not use this therapy in this setting</td>
</tr>
<tr>
<td>Duration of osteoclast-targeted therapy for SRE prevention in nmCRPC</td>
<td>1 year</td>
<td>2 years</td>
<td>Until first SRE</td>
<td>Until second SRE</td>
<td>Indefinitely</td>
</tr>
<tr>
<td>0</td>
<td>0</td>
<td>2.5%</td>
<td>0</td>
<td>2.5%</td>
<td>0</td>
</tr>
</tbody>
</table>

Answers to some questions may not total 100% due to rounding.

nmCRPC, non-metastatic, castration-resistant prostate cancer; SRE, skeletal-related event.

tension, cardiovascular complications, mental impairment, seizures, among other adverse events. For example, apalutamide was associated with rash of any grade in 23.8% of patients in the SPARTAN trial (versus 5.5% for placebo). Fatigue was reported in 30.4% of nmCRPC patients treated with apalutamide, 33% of those treated with enzalutamide, and 12.1% of those treated with darolutamide, in all cases at higher rates than placebo. The panel recommendations according to specific types of toxicity from each of the three novel ARSi mirror the recommendations related to safety and tolerability discussed above, and are generally supported by indirect comparisons between the agents, which as a rule have shown a better safety profile for darolutamide than the other two agents.

**Prevention of skeletal-related events**

Bone is the leading metastatic site and a major cause of morbidity for patients with mCRPC, among whom both zoledronic acid and denosumab play a key role in delaying SREs. Only denosumab has been assessed in a randomized trial among patients with nmCRPC, and it significantly increased bone-metastasis-free survival when compared with placebo, although by only 4.2 months. Nevertheless, denosumab has not been approved for this patient population, given the unclear clinical relevance of the results. Although the literature in this regard is still relatively scant, there is no solid evidence that osteoclast-targeted therapy improves patient-relevant outcomes in patients with nmCRPC. Probably as a reflection of the literature, there was consensus among panel members that neither zoledronic acid nor denosumab are indicated to prevent SREs in patients with nmCRPC.

**Patient follow-up**

There is no high-level evidence to guide the overall strategy for following-up patients with nmCRPC on active therapy. Nevertheless, physical examination and PSA levels every 3-6 months are recommended by the vast majority of panel members; nearly half would also add a bone scan every 3-6 months, whereas 37.5% recommended imaging only in the case of symptoms. Importantly, there is no perceived role for novel imaging methods currently.

**Conclusion**

As highlighted previously, this type of survey has limitations. The opinions are elicited through a voting system, which assumes prior knowledge on the topics discussed. The recommendations by individual panel members may be influenced by individual access to newer diagnostic tools or treatment modalities; since that access may be subject to constraints in different healthcare settings in Brazil, there is a potential influence on recommendations. This may be particularly relevant for novel imaging methods. We also consider that with advances in new imaging modalities a multidisciplinary team should be an optimal approach for nmCRPC, including discussions with radiotherapists for oligometastatic disease. We should point out, however, that the extent to which lack of consensus for some of the questions was due to characteristics at the country level or at the professional level, such as respectively specificities of the healthcare system or physician specialty, lack of sufficient data, has not been ascertained in the current work. Nevertheless, the low percentages of abstentions suggest that the topics chosen are relevant in current practice and that panel...
members indeed have variable preferences for many of the clinical issues discussed. Regardless of these limitations, we believe the current recommendations—and future updates in light of new knowledge—can help practicing clinicians best provide state-of-the-art treatment to patients with nmCRPC (Table 6).

Credit Author Statement


Clinical Practice Points

• Medical oncologists and urologists managing patients with non-metastatic, castration-resistant prostate cancer face in increasing number of choices to be made regarding staging methods, antineoplastic therapy, osteoclast-targeted therapy, and patient follow-up. Importantly, novel androgen-receptor signalling inhibitors are changing the therapeutic landscape for this disease. This paper reports recommendations of an expert panel convened to address these issues.

Funding

This study was funded by Bayer.

References


